Diabetes “Cell Reset” Research Gains Media Attention

May 22, 2025 — Research originating from Shiga University of Medical Science and its spin-off Biozipcode, Inc. has been highlighted in major Japanese media, including Yahoo! News Japan and ASCII.jp. The coverage focused on a promising new therapeutic approach to diabetes that aims not only to manage blood sugar but to fundamentally repair the abnormal stem cells at the root of the disease.

The article introduced the concept of using HDAC inhibitors to “reset” bone marrow stem cells damaged by prolonged high blood sugar. Unlike conventional therapies that rely on continuous glucose control, this method seeks to restore normal cellular environments, offering the possibility of true remission. The report noted that this approach is being advanced toward practical application as an oral therapy, supported by Biozipcode’s research platform.

The feature emphasized that this work represents a shift from diabetes as a lifelong condition to diabetes as a potentially curable disease. While clinical trials and regulatory processes remain ongoing, the recognition in national outlets underscores the importance of the research. By presenting diabetes as a disease that may one day be reversible, the coverage provides hope to millions of patients worldwide.

As the research continues, Biozipcode and its partners remain committed to advancing scientific validation and transparent development. Media attention from outlets such as Yahoo! News Japan not only reflects the growing public interest in curative therapies but also highlights Japan’s role in pioneering solutions to one of the world’s most pressing chronic diseases. Further updates will be provided as the project progresses toward global clinical adoption.